Briacell Therapeutics CORP Schedule 13G passive stakes

Citadel and its affiliates, including Kenneth Griffin, have reported a beneficial ownership of 9.99% in BriaCell Therapeutics Corp. common shares.

CVI Investments, Inc. and Heights Capital Management, Inc. have disclosed a 4.9% beneficial ownership stake in BriaCell Therapeutics Corp., primarily through warrants.

An individual investor, Jeremy Myung Jae Plambeck, has filed a Schedule 13G disclosing beneficial ownership of BriaCell Therapeutics Corp. securities, including common shares, warrants, and rights, totaling 13,638.61 common shares, which the filing states represents 100% of the '13G' class of securities.

Iroquois Capital Management, Richard Abbe, and Kimberly Page have disclosed beneficial ownership of BriaCell Therapeutics Corp. common shares, with Richard Abbe holding a 9.1% stake.

Heights Capital Management, acting as investment manager for CVI Investments, Inc., has disclosed a 5.7% beneficial ownership stake in BriaCell Therapeutics Corp., holding 1,000,000 common shares.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed a beneficial ownership of 4.9% of BriaCell Therapeutics Corp.'s common shares, primarily through warrants.

3i, LP, along with 3i Management LLC and Maier Joshua Tarlow, has filed an Amendment No. 1 to Schedule 13G, indicating they are no longer beneficial owners of more than 5% of BriaCell Therapeutics Corp.'s common shares.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed an 8.6% beneficial ownership stake in BriaCell Therapeutics Corp., totaling 489,200 common shares.

A group comprising 3i, LP, 3i Management LLC, and Maier Joshua Tarlow has disclosed a 9.9% beneficial ownership stake in BriaCell Therapeutics Corp., holding 369,000 common shares.